Trial Profile
An Open-label, Randomized, 3-period, 3-treatment Crossover Study to Evaluate the Effect of High-fat, High-calorie Food and Standard Food on the Single-dose Pharmacokinetics of Milademetan in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 21 Feb 2024
Price :
$35
*
At a glance
- Drugs Milademetan (Primary)
- Indications Acute myeloid leukaemia; Lymphoma; Multiple myeloma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Daiichi Sankyo Inc
- 26 Sep 2018 Status changed from active, no longer recruiting to completed.
- 03 Sep 2018 New trial record